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Abstract
Background: We describe the accumulation of HIV-1 drug resistance and its effect on the activity of next-line
components in patients with virological failure (HIV-1 RNA >1000 copies/mL) after 1 year (t1) of first-line antiretroviral
therapy (ART) not switching to second-line drugs for one additional year (t2) in low-middle income countries (LMIC).
Methods and results: We selected 48 patients from the DREAM cohort (Maputo, Mozambique); their median pre-ART
CD4+ cell count was 165 cells/μl. At t1 patients were receiving ART since a median of 12.2 months (mainly zidovudine/
lamivudine/nevirapine), their median HIV RNA was 3.8 log10 copies/mL, 43 (89.6%) presented at least one resistance-
associated mutation (RAM), most frequently for lamivudine/emtricitabine, nevirapine and efavirenz. Resistance to
tenofovir, was 10% at 1 year and higher than 20% at 2 years, while projection at 3 years was >30%. At t2, 42 (89.4%)
had a predicted low-level or higher resistance to at least 1 s-line drug. At t1, the frequency of RAM in patients with a
lower adherence to pharmacy appointments (<95%) was significantly lower (12/20, 60% for NRTI and 14/20, 70% for
NNRTI) than in those with a better adherence (26/28, 92.8% for NRTI and 25/28, 89.3% for NNRTI) (OR 0.12, 95%
CI 0.02–0.63, p = 0.012 and OR 0.28, 95% CI 0.06–1.29, p = 0.103, respectively). Overall thymidine analogue
mutations (TAMs) accumulation rate was 0.32/year, 0.50/year in the subgroup with HIV RNA >10,000 copies/mL;
NNRTI RAM accumulation rate was 0.15/year, 0.40/year in the subgroup with HIV RNA >10,000 copies/mL.
Conclusions: While the activity of NNRTIs is compromised early during failure, tenofovir and zidovudine activity are
reduced more frequently after 1 year of documented virological failure of thymidine analogue-based first-line ART, with
RAMs accumulating faster in patients with higher viral loads. The present observation may help informing decisions on
when to switch to a second line ART in patients on virological failure in LMIC.
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Background
As of December 2016, 19,5 million people were receiving
antiretroviral therapy (ART) word-wide. As antiretroviral
treatment is rapidly being scaled up, HIV drug resistance
is emerging and increasing at the global level. WHO
recently reported that levels of pre-treatment drug resist-
ance (PDR) to nevirapine and efavirenz, the two most
affordable non-nucleoside reverse transcriptase inhibitors
(NNRTIs) used in the first-line ART in resource-limited
settings, was 10% or above in 6 of 11 countries performing
nationally representative HIV drug resistance (DR)
surveys, 3 out of 4 in Africa [1]. According to a systematic
review, the estimated annual incremental rate of PDR to
NNRTIs ranged between 15% and 29% in Africa [2]. In
addition, NNRTI resistance among people with unsup-
pressed viral load on first-line NNRTI regimens ranged
from 47% to 90%. A systematic review of studies of
acquired drug resistance (ADR) in adults from 30 low-
middle income countries published between 2014 and
2016 found that 68% of those failing NNRTI regimens had
one or more resistance mutation after a median time on
ART of 15 months. Resistance was more frequent for
NNRTI (61%), as for nucleoside/nucleotide reverse tran-
scriptase inhibitors (NRTI) (55%) [1]. Viral load monitoring
is recommended by WHO in order to diagnose and con-
firm ART failure and provide an early and more accurate
indication to switch treatment from first-line to second-
line drugs, reducing the accumulation of resistance
mutations [3]. Lower viral load is associated with less
HIV-1 resistance mutations to all drug classes and viral
load monitoring is expected to significantly reduce the
emergence of acquired HIV drug resistance [3–8]. WHO
consolidated HIV guidelines recommend a NNRTIs-based
regimen as first line ART [3]. After failure patients may be
switched to boosted protease-inhibitors (PIs)-based
second-line ART [3]. However, given the paucity of next
treatment lines in low-middle income countries (LMIC),
the correct switching time should, among others, be
informed by the probability of accumulating resistance to
the NRTI agents included in the second line at a given
time of virological failure [3, 6–9]. Objectives of this study
are to describe the accumulation of HIV-1 drug resistance
and its effect on the activity of next-line therapy compo-
nents in patients undergoing viral load monitoring and
showing virological failure after 1 year of first-line ART but
not switching to second-line ART for one additional year.
Methods
A retrospective longitudinal cohort study was performed
with parameters extracted from the Drug Resource
Enhancement against AIDS and Malnutrition (DREAM)
database for HIV-infected patients. DREAM is a pro-
gram of care for people with HIV designed and managed
by the Community of Sant’Egidio (Italy), which is now
working in ten African countries including Mozambique
[3, 10]. The DREAM program offers free of charge state-
of-the-art treatment, diagnostic facilities and nutritional
supplementation to all HIV- infected patients within
centers from the public sector [3, 10]. Antiretroviral
therapy is supplemented by the governmental program
following National guidelines. Patients on ART perform
plasma viral load monitoring at yearly intervals. We
selected patients from 3 sites in Maputo (Mozambique)
who a) were on a first-line ART b) had an HIV RNA
>1000 copies/mL after 1 year (t1) and after 2 years (t2)
of ART without switching to a second-line regimen and
c) had a stored plasma sample at t1 and t2. We also con-
sidered: t2^: 2 years after ART initiation (1 year after
first documented virological failure) considering historical
genotype; t3*: 3 years after ART initiation (2 years after
first documented virological failure), projected results
assuming a continuous linear accumulation of resistance
mutations and historical genotype at year 2 (cumulating
resistance of t1 + t2). Genotyping of reverse transcriptase
(RT) and protease was performed at t1 and t2 by the
Trugene HIV-1 genotyping method (Siemens Health Care
Diagnostics, NY, USA). Proportion of subjects with major
resistance associated mutations (RAM) (International Anti-
viral Society-USA list 2014) to NRTIs, thymidine analogue
mutations (TAMs) and NNRTI RAM and with resistance
to individual drugs as interpreted by Stanford’s HIVdb 7.0
system (considering at least low level resistance, LLR to
each drug) was calculated. Adherence was measured by
per cent on time pharmacy appointment keeping, allowing
a delay tolerability of 10 days. The protocol was approved
by the National Ethics Committee from Mozambique
(approval n. 384/CNBS/12 on October 18, 2012).
Statistical analysis
Baseline characteristics of study patients were described
using standard descriptive statistics. Associations
between socio-demographic and HIV-related variables
were assessed using the Chi-square test for categorical
variables and Student’s t-test or the Mann – Whitney
test for continuous variables, as required. Association
between adherence to pharmacy appointments and
resistance mutations was analyzed by logistic regression.
Data were analyzed using SPSS software package
(version 18.0 Chicago, IL).
Results
There were 48 eligible patients enrolled in the study: 24
(50%) were males. At baseline (time of ART initiation,
median calendar year 2010) the median patients’s age
was 35 years (inter-quartile range, IQR 28.5–37.7), the
median CD4+ cell count was 165 cells/μl, and the mean
viral load was 4.69 log10 copies/ml. Most of the patients
(95.8%) were infected with HIV-1 subtype C. At t1,
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patients were receiving ART for a median of 12.2 months
and the most frequently employed regimen was zidovu-
dine/lamivudine/nevirapine (n = 36, 75%), followed by
stavudine/lamivudine/nevirapine (n = 4, 8.3%), stavudine/
lamivudine/efavirenz (n = 3, 6.2%), zidovudine/lamivu-
dine/abacavir (n = 3, 6.2%) and zidovudine/lamivudine/
efavirenz (n = 2, 4.2%). Between t1 and t2, NRTI compo-
nents were substituted in 2 cases from zidovudine/lamivu-
dine to stavudine/lamivudine, in 2 cases from stavudine/
lamivudine to zidovudine/lamivudine and in 2 cases from
stavudine/lamivudine to tenofovir/lamivudine. Table 1
shows the main clinical and virological characteristics of
the patients at time t1 and t2. Out of 48 patients, 43
(89.6%) presented at least one RAM after one year of ART
and 34/48 (70.8%), showed at least one RAM both for
NRTI and NNRTI. The proportion of RAM showed an
increase from t1 to t2 (Fig. 1a). In relation to individual
drugs the most frequent resistance mutations were
observed for lamivudine and emtricitabine, nevirapine and
efavirenz with progressive accumulation over time
(Fig. 1b). Resistance to tenofovir, which is the cornerstone
drug of the NRTI backbone therapy for the second-line
regimen in patients failing a first-line regimen containing
thymidine-analogues was 10% at 1 year and slightly higher
than 20% at 2 years, when cumulative resistance was con-
sidered; projection at 3 years showed a > 30% probability
of tenofovir resistance. Two of 47 (4.3%) patients with a
protease sequence available had major PI resistance muta-
tions (I54T and L90 M each in one patient), conferring
LLR to atazanavir/r and lopinavir/r. We then considered
the predicted resistance to the candidate second-line regi-
mens based on WHO recommendations and the type of
first-line regimen failing. At t1 31 (64.6%) had at least LLR
to 1 second-line drug and another 5 (10.4%) to 2 drugs, so
that a total of 36 (75%) had at least 1 second-line drug
with predicted low-level or higher resistance. At t2 31
(66.0%) had at least LLR to 1 second-line drug and an-
other 11 (23.4%) to 2 drugs, so that a total of 42 (89.4%)
had at least 1 second-line drug with predicted low-level or
higher resistance.
At t1, the probability of RAM in patients on virological
failure differed based on levels of adherence to pharmacy
appointments. In particular, frequency of NRTI RAM in
patients with a lower adherence to pharmacy appoint-
ments (<95%) was significantly lower (12/20, 60%) than in
those with a better adherence (26/28, 92.8%) (OR 0.12,
95% CI 0.02–0.63, p = 0.012). The mean yearly TAMs
accumulation rate was 0.32; which rose to 0.49 in patients
with pharmacy appointment adherence >90%. In patients
with HIV-1 RNA > 10,000 copies/mL TAMs showed a
mean yearly accumulation rate of 0.50. Probability of
NNRTI resistance was also lower in less adherent patients
at t1 (14/20, 70% vs 25/28, 89.28%; OR 0.28, 95% CI 0.06–
1.29, p = 0.103). Mean NNRTI RAMs accumulation rate
was 0.15/year. In subjects with pharmacy appointment
adherence >90% the mean accumulation rate was 0.17/year.
In patients with HIV-1 RNA > 10,000 copies/mL the mean
yearly accumulation rate of NNRTI RAMs was 0.40.
Discussion
Mozambique, a sub-Saharan country with HIV prevalence
of 10.6% provides antiretroviral therapy based on a public
health approach [3, 11, 12]. Treatment options for HIV in-
fected people in low-middle income countries (LMIC) are
based on WHO guidelines [3]. First-line regimen includes
two NRTI (tenofovir or zidovudine and lamivudine or
emtricitabine) plus one NNRTI (nevirapine or efavirenz)
whereas a boosted protease inhibitors-based ART is used
as second line regimen with a substitution of the NRTIs:
tenofovir is given after zidovudine failure, while
zidovudine is recommended in the second-line after teno-
fovir has failed in the first-line regimen [3].This treatment
sequencing strategy is based on the rationale that after
virological failure with 2 NRTI + a NNRTI, the activity
of the protease inhibitors is preserved and the cross-
resistance of the alternate NRTIs is limited [3, 6, 13].
However, after tenofovir failure, HIV-1 usually selects
for RAMs such as K65R that do not affect zidovudine
activity; on the contrary zidovudine selects for TAMs
that accumulate and progressively confer increasing
cross-resistance to tenofovir. This is one of the reasons
why WHO now recommends to prefer tenofovir as
first-line regimen, but many countries still use zidovudine
due to cost and procurement issues. Viral load monitoring
to detect treatment failures, is now recommended by
WHO and, although not yet available in many areas, is
becoming increasingly accessible [3]. Consideration of the
timing of treatment switch after 1st-line ART failure is
particularly important in resource-limited settings where
salvage regimens are scarce and costly [9]. For these
reasons in LMIC, the correct switching time should also be
informed by the probability of accumulating resistance to
the subsequent treatment lines at a given time of viro-
logical failure [7, 9, 13]. In this study, we report how RAM
Table 1 Clinical and virological follow-up at t1 (n = 48 patients)
and t2 (n = 47 patients)
t1 t2
CD4 count (cells/μl)a 234 (113–322) 236 (136–386)
HIV RNA (log10 copies/ml)
a 3.8 (3.5–4) 3.9 (3,5–4.5)
Hb (g/dL)a 12.6 (11.3–13.1) 12.1 (11.2–13.3)
BMI (Kg/m2)a 22.2 (20.7–25.3) 21.9 (20.5–24.7)
Adherence (%)a 100 (92–100) 100 (92–100)
Percent of patients with <95%
adherence to pharmacy appointments
41.7 41.3
BMI Body mass index
amedian (IQR)
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accumulate after virological failure of a thymidine
analogue-based first-line regimen in a resource-limited
setting. In particular, we show that cross-resistance to
tenofovir was still limited when failure was detected at
1 year after ART initiation. After 2 years and, in projec-
tion, after 3 years, cross-resistance to tenofovir accumu-
lated significantly. This lead to a significant accumulation
of resistance to drugs that, based on WHO guidelines,
would have been used for the second-line regimen: a pre-
dicted low-level or higher resistance to at least 1 drug of
the second-line regimen rose from 75% of cases at t1 to
89% at t2, while 10% at t1 and 23% at t2 showed a pre-
dicted resistance to 2 second-line drugs. Previous studies
have anayzed the accumulation of drug resistance muta-
tions in patients failing first-line regimens in Sub-Saharan
Africa. In a retrospective study in South Africa, in 43 pa-
tients performing sequential resistance tests with a median
interval of 5 months, RAMs accumulated at a mean of
0.07/month of drug exposure [14]. In a prospective cohort
of Zambian children on first-line ART, 6 had sequential
a
b
Fig. 1 a Proportion of patients with major resistance mutations at t1* (first documented HIV RNA >1000 copies/mL at 1 year of ART) and t2
*(continued HIV RNA >1000 copies/mL at 2 years of ART). t2^ represents the cumulative resistance summing resistance at t1 and t2. t3 represents
the projection of resistance at 3 years based on t1 and t2^ and assuming absence of resistance at baseline. b Proportion of patients with predicted
resistance to individual drugs at t1 and t2 and the projection at 3 years. * t1 total patients n = 48, t2 total patients n = 47; NRTI, nucleoside/nucleotide
reverse-transcriptase inhibitor; NNRTI, non-nucleoside reverse-transcriptase inhibitor; PIs, protease inhibitors; RAM, resistance-associated mutations; TAM
thymidine analog mutation; LLR, low-level resistance according to the interpretation by hivdb v 7.0; ZDV, zidovudine; 3TC, lamivudine; TDF, tenofovir;
NVP, nevirapine; EFV, efavirenz; ETR, etravirine
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genotypes while failing on stavudine/lamivudine/nevira-
pine and showed an accumulation rate of 0.59 TAMs/
year [15]. In a retrospective analysis of a randomized
study performed in African countries on 36 genotype
pairs from weeks 48 and 96 of first-line ART, the mean
TAMs accumulation rate was 1.50/year in nevirapine-
treated participants and 1.82/year in abacavir-treated par-
ticipants [16]. In a retrospective analysis of adults and
children failing NNRTI-based first-line ART, NNRTI re-
sistance mutations accumulated at 0.62/year and NRTI re-
sistance mutations at 0.84/year [17]. In our study we
observed a mean TAM accumulation rate of 0.32/year;
which rose to 0.49/year in patients with a pharmacy refill
adherence >90%. The yearly accumulation rate of NNRTI
resistance mutations was 0.15, rising at 0.17 in adherent
patients. An hypothesis for the reason for the lower rate
of resistance accumulation in this cohort as compared to
previous reports may be the availability of viral load moni-
toring. Indeed, patients included here were selected
among those not switching to second-line for one year
despite documented virologic failure. The population in-
cluded showed relatively low viral loads at failure, and this
might have been a reason for keeping them on first-line,
prompting adherence interventions before switching to
second-line. This probably selected a population at lower
risk of resistance accumulation, as reported by other stud-
ies relating drug resistance accumulation to viral load [4,
18]. In agreement with this, patients with an HIV-1 RNA
>10,000 copies/mL in this study showed higher yearly ac-
cumulation rates for TAMs and NNRTI resistance muta-
tions (0.50 and 0.40, respectively), values that are closer to
those provided by previous reports. Our findings may rep-
resent a practical indication for the management of pa-
tients with virological failure in this settings. In particular,
after initial detection of virological failure patients may
still benefit from adherence counselling strategies without
major risk of accumulating significant cross-resistance to
second-line drugs. However, the risk of resistance accu-
mulation is higher in patients with an HIV-1 RNA above
10,000 copies/ml, and if virological failure persists subse-
quently, despite adherence implementation, a switch to
second-line ART should be recommended, as RAM will
accumulate in the majority of patients. Our findings
should be interpreted with caution given the limited sam-
ple size and the retrospective design of the study and re-
quire validation in a prospective study. Moreover, our
sequencing technique did not cover the mutation N348I
in the connection domain, which is frequently selected by
nevirapine and thymidine analogues in subtype C, and
slightly reduces susceptibility to NNRTIs and zidovudine,
so our analyses may have slightly underestimated resist-
ance to these agents [19]. However, the accurate patients
selection and follow up and the contemporary longitu-
dinal assessment of viral load, resistance and adherence at
specified times on ART represent strong points of this co-
hort study. It is important to consider that studies in Sub-
Saharan Africa have shown that viral load could be suc-
cessfully re-suppressed with boosted PI-based second-line
regimens despite the presence of NRTI resistance after
first-line failure. One observational cohort study showed
successful virologic suppression with second-line drugs,
despite 53% were predicted to receive partially active regi-
mens due to drug resistance [20]; moreoever, in a random-
ized clinical trial [21] response to a second-line regimen
based on boosted PI +2–3 NRTIs was better as compared
to a boosted PI + raltegravir or boosted PI monotherapy
despite NRTIs had no predicted activity due to resistance
mutations; finally, in another randomized trial, the major
determinant of response to boosted PI +2–3 NRTIs as
second-line regimen was adherence but not baseline resist-
ance [22]. Therefore, our findings on NRTI RAM accumu-
lation on first-line failing patients may have limited
implications for clinical practice given the residual activity
of a regimen based on boosted PI + NRTIs. It remains to
be established whether the introduction of dolutegravir in
the recommended first-line or second-line regimens will
change this scenario.
Conclusions
While the activity of NNRTIs is compromised early
during failure, tenofovir and zidovudine activity begin
to be reduced more frequently after 1 year of docu-
mented virological failure of thymidine analogue-based
first-line ART. Higher viral load at failure is associated
with a faster rate of resistance accumulation. The
present observation may inform decisions on when to
switch to a second line therapy in patients on viro-
logical failure in LMIC settings.
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